Tien-Li Lee - 11 Jun 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Nelson Sun, as Attorney-in-Fact
Issuer symbol
AARD
Transactions as of
11 Jun 2025
Transactions value $
$0
Form type
4
Filing time
13 Jun 2025, 16:05:19 UTC
Previous filing
19 Feb 2025
Next filing
29 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Tien-Li Chief Executive Officer, Director, 10%+ Owner C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO /s/ Nelson Sun, as Attorney-in-Fact 13 Jun 2025 0001940120

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AARD Stock option (right to buy) Award $0 +550K $0.00 550K 11 Jun 2025 Common Stock 550K $11.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option shall vest on June 11, 2026, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.